초록

The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

대표청구항 ▼

1. An isolated antibody comprising a light chain variable region (VL), a heavy chain variable region (VH), and a heavy chain constant region (CH), wherein the antibody binds to human neonatal Fc receptor (FcRn); and wherein the VL comprises:(i) a VL CDR1 comprising the amino acid sequence TGTGSDVGSY

1. An isolated antibody comprising a light chain variable region (VL), a heavy chain variable region (VH), and a heavy chain constant region (CH), wherein the antibody binds to human neonatal Fc receptor (FcRn); and wherein the VL comprises:(i) a VL CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:14);(ii) a VL CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO:15); and(iii) a VL CDR3 comprising the amino acid sequence SSYAGSGIYV (SEQ ID NO:12) or ASYAGSGIYV (SEQ ID NO:13); andthe VH comprises:(i) a VH CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:22);(ii) a VH CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO:23); and(iii) a VH CDR3 comprising the amino acid sequence LAIGDSY (SEQ ID NO:24); andthe CH has a deletion corresponding to the C-terminal lysine residue at the last position of SEQ ID NO:17. 2. The isolated antibody of claim 1, wherein the VL of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 11. 3. The antibody of claim 1, wherein the antibody binds human FcRn with a dissociation constant (KD) of less than 10 nM. 4. The antibody of claim 1, wherein the antibody is a human or humanized antibody or is non-immunogenic in a human. 5. The antibody of claim 1, wherein the antibody is chimeric. 6. The antibody of claim 1, wherein the antibody is selected from the group consisting of Fab, F(ab)′2, Fv, and scFv. 7. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 8. An isolated nucleic acid comprising a sequence that encodes the antibody of claim 1. 9. A vector comprising the nucleic acid of claim 8. 10. An isolated host cell comprising the vector of claim 9. 11. A method of detecting FcRn in a sample, the method comprising: (a) contacting the sample with the antibody of claim 1, and(b) detecting an interaction between the antibody and FcRn if present. 12. A method of detecting FcRn in a subject, the method comprising: (a) administering to the subject the antibody of claim 1, and(b) detecting an interaction between the antibody and FcRn if present. 13. A method of modulating FcRn activity, the method comprising contacting FcRn with an effective amount the antibody of claim 1, thereby modulating the activity of FcRn. 14. A method of treating an autoimmune disorder in a subject, the method comprising administering to the subject the antibody of claim 1 in an amount sufficient to treat the autoimmune disorder. 15. A method of modulating the half-life and/or levels of circulating IgG in a subject, the method comprising administering to the subject the antibody of claim 1 in an amount effective to modulate the half-life and/or levels of circulating IgG in the subject. 16. A method of modulating FcRn activity, the method comprising contacting FcRn with the antibody of claim 1, thereby modulating the activity of FcRn. 17. A method of modulating the half-life and/or levels of circulating IgG in a subject, the method comprising administering to the subject the antibody of claim 1 in an amount effective to modulate the half-life and/or levels of circulating IgG in the subject.